PE20191817A1 - Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) - Google Patents
Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)Info
- Publication number
- PE20191817A1 PE20191817A1 PE2019002310A PE2019002310A PE20191817A1 PE 20191817 A1 PE20191817 A1 PE 20191817A1 PE 2019002310 A PE2019002310 A PE 2019002310A PE 2019002310 A PE2019002310 A PE 2019002310A PE 20191817 A1 PE20191817 A1 PE 20191817A1
- Authority
- PE
- Peru
- Prior art keywords
- irak4
- interleukin
- inhibitors
- kinase
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Referido a un compuesto de formula I, en donde X es CR4 o N; Y es CR5 o N; o una sal o un profarmaco del mismo. Un compuesto preferido es 3-(((2S,3S)-3-etil-4,4-difluoro-5-oxopirrolidin-2-il)metoxi)-5-metoxitieno[3,2-b] piridin-6-carboxamida. Estos compuestos de tienopiridinas y benzotiofenos son inhibidores de cinasa 4 asociada al receptor de interleucina 1 (IRAK4). Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto su uso para tratar, prevenir o ralentizar enfermedades inflamatorias y autoinmunitarias, o para el tratamiento contra el cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504956P | 2017-05-11 | 2017-05-11 | |
| PCT/US2018/031945 WO2018209012A1 (en) | 2017-05-11 | 2018-05-10 | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191817A1 true PE20191817A1 (es) | 2019-12-27 |
Family
ID=62245511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002310A PE20191817A1 (es) | 2017-05-11 | 2018-05-10 | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10829496B2 (es) |
| EP (1) | EP3621960B1 (es) |
| JP (1) | JP7154229B2 (es) |
| KR (1) | KR102604900B1 (es) |
| CN (1) | CN110612298B (es) |
| AR (1) | AR111689A1 (es) |
| AU (1) | AU2018265130B2 (es) |
| BR (1) | BR112019023290A2 (es) |
| CA (1) | CA3062602A1 (es) |
| CL (1) | CL2019003198A1 (es) |
| CO (1) | CO2019012494A2 (es) |
| CY (1) | CY1124552T1 (es) |
| DK (1) | DK3621960T3 (es) |
| EA (1) | EA039189B1 (es) |
| ES (1) | ES2889926T3 (es) |
| HR (1) | HRP20211583T1 (es) |
| HU (1) | HUE056493T2 (es) |
| IL (1) | IL270494B (es) |
| LT (1) | LT3621960T (es) |
| MX (1) | MX2019012929A (es) |
| MY (1) | MY200228A (es) |
| PE (1) | PE20191817A1 (es) |
| PL (1) | PL3621960T3 (es) |
| PT (1) | PT3621960T (es) |
| RS (1) | RS62430B1 (es) |
| SI (1) | SI3621960T1 (es) |
| SM (1) | SMT202100568T1 (es) |
| TW (1) | TW201900640A (es) |
| WO (1) | WO2018209012A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| BR112021010484A2 (pt) | 2018-11-30 | 2021-08-24 | Kymera Therapeutics, Inc. | Degradadores de irak e usos dos mesmos |
| TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| JP7570399B2 (ja) | 2019-07-18 | 2024-10-21 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用な三環式ヘテロアリール化合物 |
| EP3999512B1 (en) | 2019-07-18 | 2023-08-23 | Bristol-Myers Squibb Company | Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as irak4 inhibitors |
| EP4004000B1 (en) * | 2019-07-23 | 2025-07-09 | Bristol-Myers Squibb Company | Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors |
| EP4010317B1 (en) | 2019-08-06 | 2024-06-19 | Bristol-Myers Squibb Company | Bicyclic heterocyclic compounds useful as irak4 inhibitors |
| CN115052627A (zh) | 2019-12-17 | 2022-09-13 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US12391702B2 (en) | 2020-02-03 | 2025-08-19 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors |
| CN111285844B (zh) * | 2020-02-24 | 2022-08-12 | 河南师范大学 | 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| AU2022220043A1 (en) | 2021-02-15 | 2023-08-31 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| IL308314A (en) | 2021-05-07 | 2024-01-01 | Kymera Therapeutics Inc | CDK2 compounds and their uses |
| WO2023076556A1 (en) | 2021-10-29 | 2023-05-04 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| WO2023147594A2 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8627698D0 (en) * | 1986-11-20 | 1986-12-17 | Boots Co Plc | Therapeutic agents |
| WO2002102800A1 (en) | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| US7449456B2 (en) | 2002-06-28 | 2008-11-11 | Astellas Pharma, Inc. | Diaminopyrimidinecarboxamide derivative |
| ATE433967T1 (de) | 2003-01-17 | 2009-07-15 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| CN1820001A (zh) | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经取代的杂环二芳基胺类似物 |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| AR053158A1 (es) | 2005-03-09 | 2007-04-25 | Schering Corp | Compuestos para inhibir la actividad de quinesina de ksp |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| CN101522687A (zh) | 2006-01-30 | 2009-09-02 | 阿雷生物药品公司 | 用于癌症治疗的杂二环噻吩化合物 |
| RU2471793C2 (ru) | 2007-06-08 | 2013-01-10 | Байер Кропсайенс Аг | Фунгицид на основе гетероциклил-пиримидинил-аминопроизводных |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| JP5254693B2 (ja) | 2008-07-30 | 2013-08-07 | 三菱重工業株式会社 | Ｎｉ基合金用溶接材料 |
| EP2361902A4 (en) | 2008-11-21 | 2012-04-25 | Astellas Pharma Inc | 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG |
| JP5542692B2 (ja) | 2008-11-28 | 2014-07-09 | 興和株式会社 | ピリジン−３−カルボキシアミド誘導体 |
| US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| WO2010144647A1 (en) | 2009-06-12 | 2010-12-16 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| BR112012004843A2 (pt) | 2009-09-03 | 2019-09-24 | Allergan Inc | compostos como moduladores de tirosina cinase |
| CA2778979C (en) | 2009-10-30 | 2018-04-24 | Janssen Pharmaceutica Nv | Phenoxy-substituted pyrimidines as opioid receptor modulators |
| EP2532656A1 (en) | 2010-02-01 | 2012-12-12 | Nippon Chemiphar Co., Ltd. | Gpr119 agonist |
| WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
| AU2012249240A1 (en) | 2011-04-29 | 2013-11-07 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitors |
| EP2802579B1 (en) | 2012-01-13 | 2016-04-13 | Bristol-Myers Squibb Company | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| ES2686500T3 (es) | 2012-01-13 | 2018-10-18 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas |
| JP6096807B2 (ja) | 2012-01-13 | 2017-03-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼ阻害剤として有用なトリアゾリル置換されたピリジル化合物 |
| JP6215338B2 (ja) | 2012-11-08 | 2017-10-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 |
| SG11201503397YA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| EP2922841B8 (en) | 2012-11-08 | 2017-08-02 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| CA2944475C (en) | 2014-04-04 | 2018-07-10 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds |
| EP3268003B1 (en) * | 2015-03-12 | 2020-07-29 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of irak4 activity |
| US10155765B2 (en) * | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| TW201718571A (zh) | 2015-06-24 | 2017-06-01 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| AR105114A1 (es) | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituida con heteroarilo |
| KR102029124B1 (ko) * | 2015-08-27 | 2019-10-07 | 화이자 인코포레이티드 | Irak4 조정제로서의 비시클릭-융합된 헤테로아릴 또는 아릴 화합물 |
-
2018
- 2018-05-10 KR KR1020197036216A patent/KR102604900B1/ko active Active
- 2018-05-10 US US16/612,478 patent/US10829496B2/en active Active
- 2018-05-10 AR ARP180101237A patent/AR111689A1/es unknown
- 2018-05-10 HU HUE18727589A patent/HUE056493T2/hu unknown
- 2018-05-10 ES ES18727589T patent/ES2889926T3/es active Active
- 2018-05-10 LT LTEPPCT/US2018/031945T patent/LT3621960T/lt unknown
- 2018-05-10 TW TW107115845A patent/TW201900640A/zh unknown
- 2018-05-10 SI SI201830426T patent/SI3621960T1/sl unknown
- 2018-05-10 EA EA201992674A patent/EA039189B1/ru unknown
- 2018-05-10 SM SM20210568T patent/SMT202100568T1/it unknown
- 2018-05-10 RS RS20211247A patent/RS62430B1/sr unknown
- 2018-05-10 CN CN201880031240.4A patent/CN110612298B/zh active Active
- 2018-05-10 PT PT187275896T patent/PT3621960T/pt unknown
- 2018-05-10 CA CA3062602A patent/CA3062602A1/en active Pending
- 2018-05-10 MY MYPI2019006520A patent/MY200228A/en unknown
- 2018-05-10 PE PE2019002310A patent/PE20191817A1/es unknown
- 2018-05-10 PL PL18727589T patent/PL3621960T3/pl unknown
- 2018-05-10 HR HRP20211583TT patent/HRP20211583T1/hr unknown
- 2018-05-10 JP JP2019561740A patent/JP7154229B2/ja active Active
- 2018-05-10 WO PCT/US2018/031945 patent/WO2018209012A1/en not_active Ceased
- 2018-05-10 AU AU2018265130A patent/AU2018265130B2/en not_active Expired - Fee Related
- 2018-05-10 DK DK18727589.6T patent/DK3621960T3/da active
- 2018-05-10 BR BR112019023290-7A patent/BR112019023290A2/pt not_active Application Discontinuation
- 2018-05-10 EP EP18727589.6A patent/EP3621960B1/en active Active
- 2018-05-10 MX MX2019012929A patent/MX2019012929A/es unknown
-
2019
- 2019-11-07 CO CONC2019/0012494A patent/CO2019012494A2/es unknown
- 2019-11-07 IL IL270494A patent/IL270494B/en unknown
- 2019-11-07 CL CL2019003198A patent/CL2019003198A1/es unknown
-
2021
- 2021-10-07 CY CY20211100874T patent/CY1124552T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191817A1 (es) | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) | |
| MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
| CO2020013865A2 (es) | Análogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor | |
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| PH12020500485A1 (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| PH12017501326A1 (en) | Tgf-� inhibitors | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| MX2018015892A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| PE20091720A1 (es) | Compuestos de benzopirano y benzoxepina como inhibidores de pi3k | |
| PE20151939A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| CR20110013A (es) | Derivados de Heteroarilo como Inhibidores de DGAT1 | |
| ECSP11011258A (es) | Pirimidinas fusionadas | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| NI201300111A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
| EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
| EA201692265A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| UY36708A (es) | MODULADORES DE ROR GAMMA (RORy) | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| MX390051B (es) | Antagonistas de ep4. | |
| BR112017009012A2 (pt) | derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso | |
| SA520412289B1 (ar) | مركبات مثبط الهدف الميكانيكي للراباميسين | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia |